The Day Two Advantage: A Retrospective Paired Analysis of Consecutive HPC (A) Collections
Journal of Clinical Apheresis · 2025
DOI: 10.1002/jca.70046 ↗At a glance
Journal article in Journal of Clinical Apheresis, 2025. Written by Yandy Marx Castillo-Aleman and 11 co-authors. Institution: Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, UAE. Major MEDLINE topics: Blood Component Removal, Hematopoietic Stem Cells. 17 references.
Abstract (original language)
The hematopoietic progenitor cell apheresis [HPC(A)] is a cornerstone of stem cell transplantation. While multiple apheresis sessions are common in clinical practice, few studies have examined the procedural variability within the same donor across consecutive collections. This study aims to compare changes in the efficiency metrics between the first and second HPC(A) procedures. A retrospective analysis was conducted on paired HPC(A) procedures performed on the same donor between January 2023 and May 2025 at the Abu Dhabi Stem Cells Center. The predefined parameters, including the collection efficiencies (CE 1 , CE 2 , cruCE), performance ratio (PR), and total volume processed (TVP), were compared using the Wilcoxon signed‐rank tests. Effect sizes were calculated using Cohen's r , and associations between variables were assessed using the Spearman correlation. Of the 215 procedures screened, 90 met the inclusion criteria. Despite similar preapheresis CD34 + cell counts and flow rates, second‐day procedures demonstrated significantly improved CE 1 , CE 2 , and PR, with lower TVP. A large effect size was observed for the TVP/total blood volume (TBV) ratio ( r = 0.63), and moderate‐to‐large effect sizes for CE 2 ( r = 0.41), PR ( r = 0.47), and CE 1 ( r = 0.47). CE 1 and CE 2 correlated strongly with PR across both sessions, while CE 2 correlated positively with TVP/TBV on day 1 ( ρ = 0.47) and negatively on day 2 ( ρ = −0.40). Second‐day HPC(A) sessions yielded superior efficiency despite reduced volume, supporting the value of individualized collection planning. These “ day two advantages ” may inform refinements in yield prediction and highlight the need for prospective studies to optimize apheresis strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, UAE.
- Yas Clinic Khalifa City (YCKC) Hospital, Abu Dhabi, UAE.
- College of Medicine and Health Sciences (UAE University), Abu Dhabi, UAE.
ORCID profiles: Yandy Marx Castillo-Aleman, Carlos Agustin Villegas-Valverde, Antonio Alfonso Bencomo-Hernandez, Shinnette Lumame, Charisma Castelo, Jay Mary Rose-Roque, Marlene Cato, Nameer Al-Saadawi, Mohamed Ibrahim Abu-Haleeqa, Inas El-Najjar, Yendry Ventura-Carmenate, Fatema Mohammed Al-Kaabi
Cite
APA
Castillo-Aleman, Y. M., Villegas-Valverde, C. A., Bencomo-Hernandez, A. A., Lumame, S., Castelo, C., Rose-Roque, J. M., Cato, M., Al-Saadawi, N., Abu-Haleeqa, M. I., El-Najjar, I., Ventura-Carmenate, Y., & Al-Kaabi, F. M. (2025). The Day Two Advantage: A Retrospective Paired Analysis of Consecutive HPC (A) Collections. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70046
Vancouver
Castillo-Aleman YM, Villegas-Valverde CA, Bencomo-Hernandez AA, Lumame S, Castelo C, Rose-Roque JM, et al. The Day Two Advantage: A Retrospective Paired Analysis of Consecutive HPC (A) Collections. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70046
BibTeX
@article{CastilloAleman2025,
author = {Castillo-Aleman, Yandy Marx and Villegas-Valverde, Carlos Agustin and Bencomo-Hernandez, Antonio Alfonso and Lumame, Shinnette and Castelo, Charisma and Rose-Roque, Jay Mary and Cato, Marlene and Al-Saadawi, Nameer and Abu-Haleeqa, Mohamed Ibrahim and El-Najjar, Inas and Ventura-Carmenate, Yendry and Al-Kaabi, Fatema Mohammed},
title = {The Day Two Advantage: A Retrospective Paired Analysis of Consecutive HPC (A) Collections},
journal = {Journal of Clinical Apheresis},
year = {2025},
doi = {10.1002/jca.70046}
}
EUVIMED